Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Evolution of the Envelope Glycoprotein of HIV-1 Clade B towards Higher Infectious Properties over the Course of the Epidemic.

Bouvin-Pley M, Beretta M, Moreau A, Roch E, Essat A, Goujard C, Chaix ML, Moiré N, Martin L, Meyer L, Barin F, Braibant M.

J Virol. 2018 Dec 19. pii: JVI.01171-18. doi: 10.1128/JVI.01171-18. [Epub ahead of print]

PMID:
30567994
2.

Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Stefic K, Bouvin-Pley M, Essat A, Visdeloup C, Moreau A, Goujard C, Chaix ML, Braibant M, Meyer L, Barin F.

J Virol. 2019 Jan 4;93(2). pii: e01492-18. doi: 10.1128/JVI.01492-18. Print 2019 Jan 15.

PMID:
30404804
3.

Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains.

Beretta M, Moreau A, Bouvin-Pley M, Essat A, Goujard C, Chaix ML, Hue S, Meyer L, Barin F, Braibant M; ANRS 06 Primo Cohort.

AIDS. 2018 Sep 10;32(14):1917-1926. doi: 10.1097/QAD.0000000000001906.

PMID:
29927786
4.

Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties.

Stefic K, Chaillon A, Bouvin-Pley M, Moreau A, Braibant M, Bastides F, Gras G, Bernard L, Barin F.

PLoS One. 2017 Aug 25;12(8):e0181680. doi: 10.1371/journal.pone.0181680. eCollection 2017.

5.

Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.

Hongjaisee S, Braibant M, Barin F, Ngo-Giang-Huong N, Sirirungsi W, Samleerat T.

AIDS Res Hum Retroviruses. 2017 Sep;33(9):946-951. doi: 10.1089/AID.2017.0044. Epub 2017 Jun 12.

6.

Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions.

Gasser R, Hamoudi M, Pellicciotta M, Zhou Z, Visdeloup C, Colin P, Braibant M, Lagane B, Negroni M.

Retrovirology. 2016 Jul 30;13(1):50. doi: 10.1186/s12977-016-0285-6.

7.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.

Morgand M, Bouvin-Pley M, Plantier JC, Moreau A, Alessandri E, Simon F, Pace CS, Pancera M, Ho DD, Poignard P, Bjorkman PJ, Mouquet H, Nussenzweig MC, Kwong PD, Baty D, Chames P, Braibant M, Barin F.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):237-45. doi: 10.1097/QAI.0000000000000854.

8.

Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, Nussenzweig M, Pace C, Ho D, Bjorkman PJ, Baty D, Chames P, Pancera M, Kwong PD, Poignard P, Barin F, Braibant M.

J Virol. 2014 Dec;88(23):13910-7. doi: 10.1128/JVI.02083-14. Epub 2014 Sep 17.

9.
10.

Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.

Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M.

PLoS Pathog. 2013;9(7):e1003477. doi: 10.1371/journal.ppat.1003477. Epub 2013 Jul 4.

11.

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.

Braibant M, Gong EY, Plantier JC, Moreau T, Alessandri E, Simon F, Barin F.

AIDS. 2013 May 15;27(8):1239-44. doi: 10.1097/QAD.0b013e32835ecb42.

PMID:
23343910
12.

Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.

Chaillon A, Braibant M, Hué S, Bencharif S, Enard D, Moreau A, Samri A, Agut H, Barin F.

PLoS One. 2012;7(8):e44163. doi: 10.1371/journal.pone.0044163. Epub 2012 Aug 30.

13.

The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S, Warszawski J, Barin F.

J Virol. 2012 Oct;86(19):10540-6. doi: 10.1128/JVI.00518-12. Epub 2012 Jul 18.

14.

Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.

Thenin S, Roch E, Samleerat T, Moreau T, Chaillon A, Moreau A, Barin F, Braibant M.

J Gen Virol. 2012 Jul;93(Pt 7):1495-505. doi: 10.1099/vir.0.042614-0. Epub 2012 Apr 4.

PMID:
22492917
15.

Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties.

Thenin S, Samleerat T, Tavernier E, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Barin F, Braibant M.

Virology. 2012 Apr 25;426(1):12-21. doi: 10.1016/j.virol.2012.01.017. Epub 2012 Feb 4.

16.

The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Chaillon A, Braibant M, Moreau T, Thenin S, Moreau A, Autran B, Barin F.

J Virol. 2011 Apr;85(7):3642-8. doi: 10.1128/JVI.02424-10. Epub 2011 Jan 19.

17.

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.

Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, Larsen M, Braibant M, Marcelin AG, Costagliola D, Altfeld M, Katlama C, Autran B; ORVACS Study Group.

AIDS. 2011 Jan 2;25(1):27-36. doi: 10.1097/QAD.0b013e328340fe55.

PMID:
21076273
18.

Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain.

Braibant M, Xie J, Samri A, Agut H, Autran B, Barin F.

Virology. 2010 Sep 15;405(1):81-92. doi: 10.1016/j.virol.2010.05.026. Epub 2010 Jun 19.

19.

Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission.

Samleerat T, Thenin S, Jourdain G, Ngo-Giang-Huong N, Moreau A, Leechanachai P, Ithisuknanth J, Pagdi K, Wannarit P, Sangsawang S, Lallemant M, Barin F, Braibant M.

Virology. 2009 May 10;387(2):388-94. doi: 10.1016/j.virol.2009.02.024. Epub 2009 Mar 20.

20.

Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.

Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, Costagliola D, Caumes E, Clauvel JP, Autran B, Musset L; ALT ANRS CO15 Study Group.

Clin Infect Dis. 2009 Jan 1;48(1):123-32. doi: 10.1086/595013.

PMID:
19035778
21.

Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE.

Samleerat T, Braibant M, Jourdain G, Moreau A, Ngo-Giang-Huong N, Leechanachai P, Hemvuttiphan J, Hinjiranandana T, Changchit T, Warachit B, Suraseranivong V, Lallemant M, Barin F.

J Infect Dis. 2008 Sep 15;198(6):868-76. doi: 10.1086/591251.

PMID:
18700833
22.

Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies.

Braibant M, Agut H, Rouzioux C, Costagliola D, Autran B, Barin F.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):274-84. doi: 10.1097/QAI.0b013e318162cac2.

PMID:
18197126
23.

Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.

Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F.

AIDS. 2006 Oct 3;20(15):1923-30.

PMID:
16988513
24.

Structural and functional study of the phenicol-specific efflux pump FloR belonging to the major facilitator superfamily.

Braibant M, Chevalier J, Chaslus-Dancla E, Pagès JM, Cloeckaert A.

Antimicrob Agents Chemother. 2005 Jul;49(7):2965-71.

25.

Mycobacterium tuberculosis with disruption in genes encoding the phosphate binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates reduced in vivo virulence.

Peirs P, Lefèvre P, Boarbi S, Wang XM, Denis O, Braibant M, Pethe K, Locht C, Huygen K, Content J.

Infect Immun. 2005 Mar;73(3):1898-902.

26.

Antimycobacterial activity of synthetic pamamycins.

Lefèvre P, Peirs P, Braibant M, Fauville-Dufaux M, Vanhoof R, Huygen K, Wang XM, Pogell B, Wang Y, Fischer P, Metz P, Content J.

J Antimicrob Chemother. 2004 Oct;54(4):824-7. Epub 2004 Aug 18.

PMID:
15317744
27.
28.
29.

The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis.

Braibant M, Gilot P, Content J.

FEMS Microbiol Rev. 2000 Oct;24(4):449-67. Review. Erratum in: FEMS Microbiol Rev 2002 Mar;26(1):109.

30.

Characterization of a Mycobacterium bovis BCG insertion sequence related to the IS21 family.

Lefèvre P, Braibant M, Content J, Gilot P.

FEMS Microbiol Lett. 1999 Sep 15;178(2):211-7. Erratum in: FEMS Microbiol Lett 2002 Jan 22;207(1):109.

31.

Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors.

Tanghe A, Lefèvre P, Denis O, D'Souza S, Braibant M, Lozes E, Singh M, Montgomery D, Content J, Huygen K.

J Immunol. 1999 Jan 15;162(2):1113-9.

32.

Three different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCG.

Lefèvre P, Braibant M, de Wit L, Kalai M, Röeper D, Grötzinger J, Delville JP, Peirs P, Ooms J, Huygen K, Content J.

J Bacteriol. 1997 May;179(9):2900-6.

33.

A serine/threonine protein kinase from Mycobacterium tuberculosis.

Peirs P, De Wit L, Braibant M, Huygen K, Content J.

Eur J Biochem. 1997 Mar 1;244(2):604-12.

34.

A Mycobacterium tuberculosis gene cluster encoding proteins of a phosphate transporter homologous to the Escherichia coli Pst system.

Braibant M, Lefèvre P, de Wit L, Peirs P, Ooms J, Huygen K, Andersen AB, Content J.

Gene. 1996 Oct 17;176(1-2):171-6.

PMID:
8918249
35.

Identification of a second Mycobacterium tuberculosis gene cluster encoding proteins of an ABC phosphate transporter.

Braibant M, Lefèvre P, de Wit L, Ooms J, Peirs P, Huygen K, Wattiez R, Content J.

FEBS Lett. 1996 Sep 30;394(2):206-12.

36.

Structure of the Mycobacterium tuberculosis antigen 88, a protein related to the Escherichia coli PstA periplasmic phosphate permease subunit.

Braibant M, De Wit L, Peirs P, Kalai M, Ooms J, Drowart A, Huygen K, Content J.

Infect Immun. 1994 Mar;62(3):849-54.

Supplemental Content

Loading ...
Support Center